{"id":79696,"date":"2026-04-17T12:05:27","date_gmt":"2026-04-17T12:05:27","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting\/"},"modified":"2026-04-17T12:05:27","modified_gmt":"2026-04-17T12:05:27","slug":"lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/lexicon-to-present-data-at-the-american-academy-of-neurology-aan-annual-meeting\/","title":{"rendered":"Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting"},"content":{"rendered":"
\n

\n

\u00a0Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP<\/em><\/p>\n

New data on spasticity further validates the broader potential importance of the AAK1 pathway in neurologic diseases<\/em><\/p>\n

THE WOODLANDS, Texas, April 17, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.\u00a0(Nasdaq: LXRX) today announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) supporting the selection of pilavapadin 10 mg as the optimal dose for Phase 3 development will be presented on Wednesday April 22, during the American Academy of Neurology (AAN) Annual Meeting. At the meeting, the company will also present results of an evaluation of pilavapadin on spasticity-related endpoints in preclinical models of multiple sclerosis and spinal cord injury. The congress is being held April 18-22 in Chicago, Illinois.<\/p>\n

In a session titled \u201cAdditional Efficacy Data Support Selection of Pilavapadin 10 mg for Phase 3 Development in DPNP: Results From PROGRESS,\u201d Suma Gopinathan, Ph.D., Senior Vice President of Discovery at Lexicon, will present data from the study on pain outcomes as measured by the Brief Pain Inventory\u2013Diabetic Peripheral Neuropathy (BPI-DPN) patient reported instrument. Pilavapadin 10 mg achieved a nominally significant reduction in Average Pain at Week 8 versus placebo, with concordant improvements in Worst and Least Daily Pain, as measured by BPI-DPN. The 10 mg dose was generally well-tolerated over 8 weeks, with completion rates comparable to placebo and few discontinuations due to treatment emergent adverse events (TEAEs). Overall, these results provide additional support for the advancement of pilavapadin 10 mg into Phase 3 evaluation in DPNP.<\/p>\n

\u201cWe appreciate the opportunity to present additional efficacy data from the PROGRESS study to the neurology community,\u201d said Dr. Gopinathan. \u201cThese results demonstrate that pilavapadin 10 mg achieved a meaningful reduction in average pain at Week 8, with consistent improvements across other pain measures, supporting its advancement into Phase 3 development in diabetic peripheral neuropathic pain.\u201d<\/p>\n

Presentation details:<\/p>\n